ONTY—To be fair, success at the final analysis is still possible. The main problem for longs—as noted in #msg-70815718—is that we now know the efficacy is not extraordinarily strong, and hence the commercial prospects for Stimuvax are considerably bleaker even if the drug ends up being approved.
Market Data 
Markets 
AI
